AR057965A1 - Compuestos de lactama y metodos de uso de los mismos - Google Patents
Compuestos de lactama y metodos de uso de los mismosInfo
- Publication number
- AR057965A1 AR057965A1 ARP060105351A ARP060105351A AR057965A1 AR 057965 A1 AR057965 A1 AR 057965A1 AR P060105351 A ARP060105351 A AR P060105351A AR P060105351 A ARP060105351 A AR P060105351A AR 057965 A1 AR057965 A1 AR 057965A1
- Authority
- AR
- Argentina
- Prior art keywords
- cycloalkyl
- heterocycloalkyl
- alkyl
- haloalkyl
- heteroaryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
Abstract
Reivindicacion1: Un compuesto de formula (1) o sales aceptables para uso farmacéutico de los mismos, donde: Cy es arilo, heteroarilo, cicloalquilo, o heterocicloalquilo, cada uno opcionalmente sustituido con 1, 2, 3, 4, o 5 -W-X-Y-Z: L es nulo, (CR12R13)q, (CR12R13)q1O(CR12R13)q2, (CR12R13)q1S(CR12R13)q2, (CR12R13)q1SO2(CR12R13)q2, (CR12R13)q1SO(CR12R13)q2, (CR12R13)q1CO(CR12R13)q2, o (CR12R13)q1CONR2a(CR12R13)q2; Q es -(CR1R2)m-A; A es cicloalquilo, heterocicloalquilo o heteroarilo, cada uno opcionalmente sustituido con 1, 2, 3, 4 o 5 -W'-X'-Y'-Z-; E es -(CR3aR3b)n1-, -(CR3aR3b)n2CO-, -(CR3aR3b)n2OCO-, -(CR3aR3b)n2SO-; -(CR3aR3b)n2SO2-, -(CR3aR3b)n2NR3c-, -(CR3aR3b)n2CONR3c-, -(CR3aR3b)n2NR3cCO-, o un grupo de formula (2); D1, D2, D3 y D4 se seleccionan en forma independiente entre N y CR15; R1, R2 y R2a se seleccionan en forma independiente entre H y alquilo C1-8; R3a y R3b se seleccionan en forma independiente entre H, halo, alquilo C1-4, haloalquilo C1-4, alquenilo C2-4 y alquinilo C2-4; R3c es H, alquilo C1-4, haloalquilo C1-4, alquenilo C2-4, alquinilo C2-4, o CO-(C1-4alquilo); R4, R5, R6, R7, R8, R9, R10 y R11 se seleccionan en forma independiente entre H, OC(O)Ra', OC(O)ORb', C(O)ORb', OC(O)NRc'Rd', NRc'Rd', NRc'C(O)Ra', NRc'C(O)ORb', S(O)Ra', S(O)NRc'Rd', S(O)2Ra', S(O)2NRc'Rd', ORb', SRb', halo alquilo C1-10, haloalquilo C1-10, alquenilo C2-10, alquinilo C2-10, arilo cicloalquilo, heteroarilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo, y heterocicloalquilalquilo, donde dicho alquilo C1-10, haloalquilo C1-10, alquenilo C2-10, alquinilo C2-10, arilo cicloalquilo, heteroarilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo, o heterocicloalquilalquilo, está opcionalmente sustituido con 1, 2, o 3 R14; o R4 y R5 junto con el átomo de C al cual están unidos forman un grupo cicloalquilo o heterocicloalquilo de entre 3 y 14 miembros que está opcionalmente sustituido con R14; o R6 y R7 junto con el átomo de C al cual están unidos forman un grupo cicloalquilo o heterocicloalquilo de entre 3 y 14 miembros que está opcionalmente sustituido con R14; o R8 y R9 junto con el átomo de C al cual están unidos forman un grupo cicloalquilo o heterocicloalquilo de entre 3 y 14 miembros que está opcionalmente sustituido con R14; o R10 y R11 junto con el átomo de C al cual están unidos forman un grupo cicloalquilo o heterocicloalquilo de entre 3 y 14 miembros que está opcionalmente sustituido con R14; o R4 y 6 junto con el átomo de C al cual están unidos forman un grupo cicloalquilo fusionado de entre 3 y 7 miembros o un grupo heterocicloalquilo fusionado de entre 3 y 7 miembros que está opcionalmente sustituido con R14; o R6 y R8 junto con el átomo de C al cual están unidos forman un grupo cicloalquilo fusionado de entre 3 y 7 miembros o un grupo heterocicloalquilo fusionado de entre 3 y 7 miembros que está opcionalmente sustituido con R14; o R4 y R9 juntos forman un puente alquileno C1-3 que está opcionalmente sustituido con R14; o R4 y R10 juntos forman un puente alquileno C1-3 que está opcionalmente sustituido con R14; o R6 y R10 juntos forman un puente alquileno C1-3 que está opcionalmente sustituido con R14; o R9 y R10 juntos forman un puente alquileno C1-3 que está opcionalmente sustituido con R14; R12 y R13 se seleccionan en forma independiente entre H, halo, alquilo C1-4, haloalquilo C1-4, cicloalquilo, heteroarilo, heterocicloalquilo, CN, NO2, ORa', SRa', C(O)Rb', C(O)NRc'Rd', C(O)ORa', OC(O)Rb', OC(O)NRc'Rd', S(O)Rb', S(O)NRc'Rd', S(O)2Rb', y S(O)2NRc'Rd'; R14 es halo, alquilo C1-4, haloalquilo C1-4, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, CN, NO2, ORa', SRa', C(O)Rb', C(O)NRc'Rd', C(O)ORa', OC(O)Rb', OC(O)NRc'Rd', NRc'Rd', NRc'C(O)Rd', NRc'C(O)ORa', S(O)Rb', S(O)NRc'Rd', S(O)2Rb', o S(O)2NRc'Rd'; R15 es H, halo, alquilo C1-4, haloalquilo C1-4, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, CN, NO2, ORaö, SRaö, C(O)Rbö, C(O)NRcöRdö, C(O)ORaö, OC(O)Rbö, OC(O)NRcöRdö, NRcöRdö, NRcöC(O)Rdö, NRcöC(O)ORaö, S(O)Rbö, S(O)NRcöRdö, S(O)2Rbö, o S(O)2NRcöRdö;W, W' y Wö se seleccionan en forma independiente entre nulo, alquilenilo C1-6, alquenilenilo C2-6, alquinilenilo C2-6, O, S, NRe, CO, COO, CONRe, SO, SO2, SONRe, y NReCONRf, donde dicho alquilenilo C1-6, alquenilenilo C2-6, alquinilenilo C2-6 está cada uno opcionalmente sustituido con 1, 2 o 3 sustituyentes seleccionados en forma independiente entre halo, OH, alcoxi C1-4, haloalcoxi C1-4, amino, alquilamino C1-4, y dialquilamino C2-8; X, X' y Xö se seleccionan en forma independiente entre nulo, alquilenilo C1-6, alquenilenilo C2-6, alquinilenilo C2-6, arilo, cicloalquilo, heteroarilo, y heterocicloalquilo, donde dicho alquilenilo C1-6, alquenilenilo C2-6, alquinilenilo C2-6, arilo, cicloalquilo, heteroarilo, o heterocicloalquilo está opcionalmente sustituido con uno o más sustituyentes seleccionados en forma independiente entre halo, alquilo C1-6, oxo, CN, NO2, OH, alcoxi C1-4, haloalcoxi C1-4, amino, alquilamino C1-4, y dialquilamino C2-8; Y, Y' y Yö se seleccionan en forma independiente entre nulo, alquilenilo C1-6, alquenilenilo C2-6, alquinilenilo C2-6, O, S, NRe, CO, COO, CONRe, SO, SO2, SONRe, y NReCONRf, donde dicho alquilenilo C1-6, alquenilenilo C2-6, alquinilenilo C2-6 está cada uno opcionalmente sustituido con 1, 2 o 3 sustituyentes seleccionados en forma independiente entre halo, OH, alcoxi C1-4, haloalcoxi C1-4, amino, alquilamino C1-4, y dialquilamino C2-8; Z, Z' y Zö se seleccionan en forma independiente entre H, halo, CN, NO2, OH, alcoxi C1-4, haloalcoxi C1-4, amino, alquilamino C1-4, dialquilamino C2-8, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilo, cicloalquilo, heteroarilo, y heterocicloalquilo, donde dicho alquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilo, cicloalquilo, heteroarilo, o heterocicloalquilo está opcionalmente sustituido con 1, 2 o 3 sustituyentes seleccionados en forma independiente entre halo, oxo, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, haloalquilo C1-4, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, halosulfanilo, CN, NO2, ORa, SRa, C(O)Rb, C(O)NRcRd, C(O)ORa, OC(O)Rb, OC(O)NRcRd, NRcRd, NRcC(O)Rd, NRcC(O)ORa, NReS(O)2Rb, C(=NRi)NRcRd, NRcC(=NRi)NRcRd, S(O)Rb, S(O)NRcRd, S(O)2Rb, y S(O)2NRcRd; donde dos -W-X-Y-Z unidos al mismo átomo forman opcionalmente un grupo cicloalquilo o heterocicloalquilo de entre 3 y 20 miembros, cada uno opcionalmente sustituido con 1, 2 o 3 -Wö-Xö-Yö-Zö; donde dos -W'-X'-Y'-Z'- unidos al mismo átomo forman opcionalmente un grupo cicloalquilo o heterocicloalquilo de entre 3 y 20 miembros, cada uno opcionalmente sustituido con 1, 2 o 3 -Wö-Xö-Yö-Zö; donde -W-X-Y-Z es distinto de H; donde -W'-X'-Y'-Z'- es distinto de H; donde -Wö-Xö-Yö-Zö- es distinto de H; Ra, Ra' y Raö se seleccionan en forma independiente entre H, alquilo C1-6, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilo, cicloalquilo, heteroarilo, y heterocicloalquilo, donde dicho alquilo C1-6, haloalquilo C1-6alquenilo C2-6, alquinilo C2-6, arilo, cicloalquilo, heteroarilo, o heterocicloalquilo está opcionalmente sustituido con H, OH, amino, halo, alquilo C1-6, haloalquilo C1-6, arilo, arilalquilo, heteroarilo, heteroarilalquilo, cicloalquilo, o heterocicloalquilo; Rb, Rb' y Rbö se seleccionan en forma independiente entre H, alquilo C1-6, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo, y heterocicloalquilalquilo, donde dicho alquilo C1-6, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilo, cicloalquilo, heteroarilo, heterocicloalquilo arilalquilo, heteroarilalquilo, cicloalquilalquilo, o heterocicloalquilalquilo está opcionalmente sustituido con H, OH, amino, halo, alquilo C1-6, haloalquilo C1-6, haloalquilo C1- 6, arilo, arilalquilo, heteroarilo, heteroarilalquilo, cicloalquilo o heterocicloalquilo; Rc y Rd se seleccionan en forma independiente entre H, alquilo C1-10, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilo, heteroarilo, cicloalquilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo y heterocicloalquilalquilo, donde dicho alquilo C1-10, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilo, heteroarilo, cicloalquilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo o heterocicloalquilalquilo está opcionalmente sustituido con H, OH, amino, halo, alquilo C1-6, haloalquilo C1-6, haloalquilo C1-6, arilo, arilalquilo, heteroarilo, heteroarilalquilo, cicloalquilo o heterocicloalquilo; o Rc y Rd junto con el átomo de N al cual están unidos forman un grupo heterocicloalquilo de 4, 5, 6 o 7 miembros; Rc' y Rd' se seleccionan en forma independiente entre H alquilo C1-10, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilo, heteroarilo, cicloalquilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo y heterocicloalquilalquilo, donde dicho alquilo C1-10, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilo, heteroarilo, cicloalquilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo o heterocicloalquilalquilo está opcionalmente sustituido con H, OH, amino, halo, alquilo C1-6, haloalquilo C1-6, haloalquilo C1-6, arilo, arilalquilo, heteroarilo, heteroarilalquilo, cicloalquilo o heterocicloalquilo; o Rc' y Rd' junto con el átomo de N al cual están unidos forman un grupo heterocicloalquilo de 4, 5, 6 o 7 miembros; Rcö y Rdö se seleccionan en forma independiente entre alquilo C1-10, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilo, heteroarilo, cicloalquilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo y heterocicloalquilalquilo, donde dicho alquilo C1-10, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilo, heteroarilo, cicloalquilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo o heterocicloalquilalquilo está opcionalmente sustituido con H, OH, amino, halo, alquilo C1-6, haloalquilo
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US74235305P | 2005-12-05 | 2005-12-05 | |
US80867806P | 2006-05-26 | 2006-05-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR057965A1 true AR057965A1 (es) | 2007-12-26 |
Family
ID=38006858
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060105351A AR057965A1 (es) | 2005-12-05 | 2006-12-04 | Compuestos de lactama y metodos de uso de los mismos |
Country Status (15)
Country | Link |
---|---|
US (1) | US8193207B2 (es) |
EP (1) | EP1957494A2 (es) |
JP (1) | JP5475288B2 (es) |
KR (1) | KR101415861B1 (es) |
AR (1) | AR057965A1 (es) |
AU (1) | AU2006322060A1 (es) |
BR (1) | BRPI0619446A2 (es) |
CA (1) | CA2630492C (es) |
CR (1) | CR9987A (es) |
EA (1) | EA200870019A1 (es) |
EC (1) | ECSP088503A (es) |
IL (1) | IL191554A0 (es) |
NZ (1) | NZ568446A (es) |
TW (1) | TW200804382A (es) |
WO (1) | WO2007067504A2 (es) |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI350168B (en) | 2004-05-07 | 2011-10-11 | Incyte Corp | Amido compounds and their use as pharmaceuticals |
EP1768954A4 (en) * | 2004-06-24 | 2008-05-28 | Incyte Corp | 2-METHYLPROPANAMIDES AND THEIR USE AS PHARMACEUTICALS |
MXPA06014573A (es) * | 2004-06-24 | 2007-03-12 | Incyte Corp | Compuestos amido y su uso como farmaceuticos. |
CA2589565A1 (en) * | 2004-06-24 | 2006-01-05 | Incyte Corporation | Amido compounds and their use as pharmaceuticals |
CA2570637A1 (en) * | 2004-06-24 | 2006-02-02 | Wenqing Yao | N-substituted piperidines and their use as pharmaceuticals |
EP1773780A4 (en) * | 2004-06-24 | 2008-01-09 | Incyte Corp | AMIDO COMPOUNDS AND USES THEREOF AS PHARMACEUTICAL PRODUCTS |
JP2008504278A (ja) * | 2004-06-24 | 2008-02-14 | インサイト・コーポレイション | アミド化合物およびその医薬としての使用 |
US20060122197A1 (en) * | 2004-08-10 | 2006-06-08 | Wenqing Yao | Amido compounds and their use as pharmaceuticals |
US8110581B2 (en) * | 2004-11-10 | 2012-02-07 | Incyte Corporation | Lactam compounds and their use as pharmaceuticals |
JP5202954B2 (ja) * | 2004-11-10 | 2013-06-05 | インサイト・コーポレイション | ラクタム化合物およびその医薬としての使用 |
KR20070097441A (ko) * | 2004-11-18 | 2007-10-04 | 인사이트 산 디에고 인코포레이티드 | 11-β 하이드록실 스테로이드 데하이드로게나제 유형 1의억제제 및 이를 사용하는 방법 |
JP2009508963A (ja) * | 2005-09-21 | 2009-03-05 | インサイト・コーポレイション | アミド化合物および医薬組成物としてのその使用 |
WO2007084314A2 (en) * | 2006-01-12 | 2007-07-26 | Incyte Corporation | MODULATORS OF 11-ß HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME |
WO2007089683A1 (en) * | 2006-01-31 | 2007-08-09 | Incyte Corporation | Amido compounds and their use as pharmaceuticals |
TW200808807A (en) * | 2006-03-02 | 2008-02-16 | Incyte Corp | Modulators of 11-β hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same |
US20070208001A1 (en) * | 2006-03-03 | 2007-09-06 | Jincong Zhuo | Modulators of 11- beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same |
WO2007130898A1 (en) * | 2006-05-01 | 2007-11-15 | Incyte Corporation | TETRASUBSTITUTED UREAS AS MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1 |
JP2009537564A (ja) * | 2006-05-17 | 2009-10-29 | インサイト・コーポレイション | 11−βヒドロキシルステロイドデヒドロゲナーゼタイプIの複素環阻害剤およびそれを用いる方法 |
JP5486928B2 (ja) * | 2007-02-26 | 2014-05-07 | ヴァイティー ファーマシューティカルズ,インコーポレイテッド | 11β−ヒドロキシステロイドデヒドロゲナーゼ1のサイクリックウレアおよびカルバメートインヒビター |
CL2008001839A1 (es) * | 2007-06-21 | 2009-01-16 | Incyte Holdings Corp | Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades. |
AU2014218443B2 (en) * | 2007-06-21 | 2016-05-19 | Incyte Holdings Corporation | Spirocycles as inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1 |
WO2009017671A1 (en) * | 2007-07-26 | 2009-02-05 | Vitae Pharmaceuticals, Inc. | Synthesis of inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 |
AR069207A1 (es) * | 2007-11-07 | 2010-01-06 | Vitae Pharmaceuticals Inc | Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1 |
CA2708303A1 (en) | 2007-12-11 | 2009-06-18 | Vitae Pharmaceuticals, Inc. | Cyclic urea inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1 |
TW200934490A (en) * | 2008-01-07 | 2009-08-16 | Vitae Pharmaceuticals Inc | Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1 |
CA2712500A1 (en) * | 2008-01-24 | 2009-07-30 | Vitae Pharmaceuticals, Inc. | Cyclic carbazate and semicarbazide inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
EP2252598A2 (en) * | 2008-02-11 | 2010-11-24 | Vitae Pharmaceuticals, Inc. | 1,3-oxazepan-2-one and 1,3-diazepan-2-one inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
EP2254872A2 (en) * | 2008-02-15 | 2010-12-01 | Vitae Pharmaceuticals, Inc. | Cycloalkyl lactame derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
US8383629B2 (en) * | 2008-02-27 | 2013-02-26 | Vitae Pharmaceuticals, Inc. | Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 |
JP5538356B2 (ja) * | 2008-03-18 | 2014-07-02 | ヴァイティー ファーマシューティカルズ,インコーポレイテッド | 11β−ヒドロキシステロイドデヒドロゲナーゼ1型の阻害剤 |
EP2291371B1 (en) | 2008-05-01 | 2015-06-10 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
JP5451752B2 (ja) * | 2008-05-01 | 2014-03-26 | ヴァイティー ファーマシューティカルズ,インコーポレイテッド | 11β−ヒドロキシステロイドデヒドロゲナーゼ1の環状インヒビター |
KR20110002492A (ko) * | 2008-05-01 | 2011-01-07 | 비타이 파마슈티컬즈, 인코포레이티드 | 11베타-하이드록시스테로이드 탈수소효소 1의 고리형 억제제 |
JP5538365B2 (ja) | 2008-05-01 | 2014-07-02 | ヴァイティー ファーマシューティカルズ,インコーポレイテッド | 11β−ヒドロキシステロイドデヒドロゲナーゼ1の環状阻害剤 |
WO2010127237A2 (en) * | 2009-04-30 | 2010-11-04 | Boehringer Ingelheim International Gmbh | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
WO2010010157A2 (en) | 2008-07-25 | 2010-01-28 | Boehringer Ingelheim International Gmbh | INHIBITORS OF 11beta-HYDROXYSTEROID DEHYDROGENASE 1 |
CN102119160B (zh) | 2008-07-25 | 2014-11-05 | 贝林格尔·英格海姆国际有限公司 | 11β-羟基类固醇脱氢酶1的环状抑制剂 |
GB0818241D0 (en) * | 2008-10-06 | 2008-11-12 | Cancer Res Technology | Compounds and their use |
AR074466A1 (es) | 2008-12-05 | 2011-01-19 | Sanofi Aventis | Piperidina espiro pirrolidinona y piperidinona sustituidas y su uso terapeutico en enfermedades mediadas por la modulacion de los receptores h3. |
WO2010089303A1 (en) | 2009-02-04 | 2010-08-12 | Boehringer Ingelheim International Gmbh | CYCLIC INHIBITORS OF 11 β-HYDROXYSTEROID DEHYDROGENASE 1 |
EP2243479A3 (en) | 2009-04-20 | 2011-01-19 | Abbott Laboratories | Novel amide and amidine derivates and uses thereof |
TW201039034A (en) * | 2009-04-27 | 2010-11-01 | Chunghwa Picture Tubes Ltd | Pixel structure and the method of forming the same |
US8680093B2 (en) | 2009-04-30 | 2014-03-25 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
US8329904B2 (en) * | 2009-05-12 | 2012-12-11 | Hoffmann-La Roche Inc. | Azacyclic derivatives |
EP2440537A1 (en) | 2009-06-11 | 2012-04-18 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 based on the 1,3 -oxazinan- 2 -one structure |
US8883778B2 (en) | 2009-07-01 | 2014-11-11 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11 beta-hydroxysteroid dehydrogenase 1 |
WO2011029896A1 (en) * | 2009-09-11 | 2011-03-17 | Glaxo Group Limited | Methods of preparation of muscarinic acetylcholine receptor antagonists |
US8871208B2 (en) * | 2009-12-04 | 2014-10-28 | Abbvie Inc. | 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors and uses thereof |
US8097634B2 (en) * | 2010-04-15 | 2012-01-17 | Hoffmann-La Roche Inc. | Azacyclic derivatives |
JP5860042B2 (ja) | 2010-06-16 | 2016-02-16 | ヴァイティー ファーマシューティカルズ,インコーポレイテッド | 置換5、6及び7員複素環、そのような化合物を含有する医薬及びそれらの使用 |
WO2011161128A1 (en) | 2010-06-25 | 2011-12-29 | Boehringer Ingelheim International Gmbh | Azaspirohexanones as inhibitors of 11-beta-hsd1 for the treatment of metabolic disorders |
CN102971320B (zh) * | 2010-07-13 | 2016-11-02 | 霍夫曼-拉罗奇有限公司 | 新型氮杂环化合物 |
US8552024B2 (en) * | 2010-08-13 | 2013-10-08 | Hoffman-La Roche Inc. | Azacyclic compounds |
AU2011325286B2 (en) | 2010-11-02 | 2015-04-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical combinations for the treatment of metabolic disorders |
AU2013337086B2 (en) * | 2012-10-08 | 2017-06-15 | Cancer Research Technology Limited | 2-aminopyridine compounds |
GB201404922D0 (en) | 2014-03-19 | 2014-04-30 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
EP3235813A1 (en) | 2016-04-19 | 2017-10-25 | Cidqo 2012, S.L. | Aza-tetra-cyclo derivatives |
TW201922758A (zh) | 2017-10-24 | 2019-06-16 | 美商歐樂根公司 | 烯胺及烯胺的非鏡像選擇性還原 |
EP3553061A1 (en) * | 2018-04-12 | 2019-10-16 | Centre National De La Recherche Scientifique (Cnrs) | New inhibitors of bone resorption |
Family Cites Families (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2312247A1 (fr) | 1975-05-30 | 1976-12-24 | Parcor | Derives de la thieno-pyridine, leur procede de preparation et leurs applications |
US4439606A (en) | 1982-05-06 | 1984-03-27 | American Cyanamid Company | Antiatherosclerotic 1-piperazinecarbonyl compounds |
JP2521999B2 (ja) * | 1986-12-27 | 1996-08-07 | 武田薬品工業株式会社 | アザスピロ化合物 |
EP0273659A1 (en) | 1986-12-27 | 1988-07-06 | Takeda Chemical Industries, Ltd. | Azaspiro compounds, their production and use |
US5206240A (en) | 1989-12-08 | 1993-04-27 | Merck & Co., Inc. | Nitrogen-containing spirocycles |
US5852029A (en) | 1990-04-10 | 1998-12-22 | Israel Institute For Biological Research | Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity |
JPH04334357A (ja) | 1991-05-02 | 1992-11-20 | Fujirebio Inc | 酵素阻害作用を有するアシル誘導体 |
DE4234295A1 (de) | 1992-10-12 | 1994-04-14 | Thomae Gmbh Dr K | Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
FR2705343B1 (fr) | 1993-05-17 | 1995-07-21 | Fournier Ind & Sante | Dérivés de beta,beta-diméthyl-4-pipéridineéthanamine, leur procédé de préparation et leur utilisation en thérapeutique. |
FR2724656B1 (fr) | 1994-09-15 | 1996-12-13 | Adir | Nouveaux derives du benzopyranne, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
FR2736053B1 (fr) | 1995-06-28 | 1997-09-19 | Sanofi Sa | Nouvelles 1-phenylalkyl-1,2,3,6-tetrahydropyridines |
EP0921125B1 (en) | 1997-12-05 | 2002-01-30 | F. Hoffmann-La Roche Ag | 1,3,8-Triazaspiro[4,5]decan-4-on derivatives |
AU2206699A (en) | 1997-12-23 | 1999-07-12 | Alcon Laboratories, Inc. | Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions |
AU1244001A (en) * | 1999-10-27 | 2001-05-08 | Cor Therapeutics, Inc. | Pyridyl-containing spirocyclic compounds as inhibitors of fibrinogen-dependent platelet aggregation |
JP2001261679A (ja) * | 2000-03-21 | 2001-09-26 | Mitsui Chemicals Inc | ピロリジノン誘導体及びそれらの製造方法並びに該化合物を含有する医薬 |
US7294637B2 (en) | 2000-09-11 | 2007-11-13 | Sepracor, Inc. | Method of treating addiction or dependence using a ligand for a monamine receptor or transporter |
WO2003000657A1 (fr) | 2001-06-20 | 2003-01-03 | Daiichi Pharmaceutical Co., Ltd. | Derives de diamine |
US6547958B1 (en) | 2001-07-13 | 2003-04-15 | Chevron U.S.A. Inc. | Hydrocarbon conversion using zeolite SSZ-59 |
GB0118238D0 (en) * | 2001-07-26 | 2001-09-19 | Smithkline Beecham Plc | Medicaments |
GB0121033D0 (en) * | 2001-08-30 | 2001-10-24 | Novartis Ag | Organic compounds |
GB0126292D0 (en) | 2001-11-01 | 2002-01-02 | Smithkline Beecham Plc | Compounds |
PE20030701A1 (es) | 2001-12-20 | 2003-08-21 | Schering Corp | Compuestos para el tratamiento de trastornos inflamatorios |
US6818772B2 (en) | 2002-02-22 | 2004-11-16 | Abbott Laboratories | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor |
US6743864B2 (en) | 2002-03-12 | 2004-06-01 | Basell Poliolefine Italia S.P.A. | Polyolefin compositions having high tenacity |
WO2003104233A1 (en) | 2002-06-07 | 2003-12-18 | Altana Pharma Ag | 4,5-dihydro-imidazo (4,5,1-ij) quinolin-6-ones derivatives and their use as poly (adp-ribosyl) transferase (parp) inhibitors |
GB0213715D0 (en) | 2002-06-14 | 2002-07-24 | Syngenta Ltd | Chemical compounds |
AU2002354054A1 (en) | 2002-10-18 | 2004-05-04 | Ono Pharmaceutical Co., Ltd. | Spiroheterocyclic derivative compounds and drugs comprising the compounds as the active ingredient |
AU2003299791A1 (en) * | 2002-12-20 | 2004-07-22 | Bayer Pharmaceuticals Corporation | Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity |
WO2004056744A1 (en) | 2002-12-23 | 2004-07-08 | Janssen Pharmaceutica N.V. | Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors |
TW200503994A (en) | 2003-01-24 | 2005-02-01 | Novartis Ag | Organic compounds |
GB0304640D0 (en) * | 2003-02-28 | 2003-04-02 | Novartis Ag | Organic compounds |
US7205318B2 (en) | 2003-03-18 | 2007-04-17 | Bristol-Myers Squibb Company | Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors |
DE602004027171D1 (de) | 2003-04-11 | 2010-06-24 | High Point Pharmaceuticals Llc | Verbindungen mit Aktivität an der 11Beta-Hydroxasteroiddehydrogenase |
WO2005007656A1 (en) * | 2003-07-18 | 2005-01-27 | Virochem Pharma Inc. | Spiro compounds and methods for the modulation of chemokine receptor activity |
WO2005047286A1 (ja) * | 2003-11-13 | 2005-05-26 | Ono Pharmaceutical Co., Ltd. | スピロ複素環化合物 |
AR046756A1 (es) | 2003-12-12 | 2005-12-21 | Solvay Pharm Gmbh | Derivados de hidronopol como agonistas de receptores orl-1 humanos. |
AU2004305321A1 (en) | 2003-12-19 | 2005-07-07 | Pfizer Inc. | Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-hsd-1) for the treatment of diabetes and obesity |
EP1716148A2 (en) | 2003-12-23 | 2006-11-02 | Arena Pharmaceuticals, Inc. | Novel spiroindoline or spiroisoquinoline compounds, methods of use and compositions thereof |
WO2005084667A1 (en) * | 2004-03-03 | 2005-09-15 | Chemocentryx, Inc. | Bicyclic and bridged nitrogen heterocycles |
MXPA06012831A (es) | 2004-05-06 | 2007-01-26 | Pfizer | Nuevos compuestos de derivados de morfolina y prolina. |
TWI350168B (en) | 2004-05-07 | 2011-10-11 | Incyte Corp | Amido compounds and their use as pharmaceuticals |
MXPA06014573A (es) | 2004-06-24 | 2007-03-12 | Incyte Corp | Compuestos amido y su uso como farmaceuticos. |
CA2589565A1 (en) | 2004-06-24 | 2006-01-05 | Incyte Corporation | Amido compounds and their use as pharmaceuticals |
CA2570637A1 (en) | 2004-06-24 | 2006-02-02 | Wenqing Yao | N-substituted piperidines and their use as pharmaceuticals |
EP1773780A4 (en) | 2004-06-24 | 2008-01-09 | Incyte Corp | AMIDO COMPOUNDS AND USES THEREOF AS PHARMACEUTICAL PRODUCTS |
EP1768954A4 (en) | 2004-06-24 | 2008-05-28 | Incyte Corp | 2-METHYLPROPANAMIDES AND THEIR USE AS PHARMACEUTICALS |
JP2008504278A (ja) | 2004-06-24 | 2008-02-14 | インサイト・コーポレイション | アミド化合物およびその医薬としての使用 |
US20060122197A1 (en) | 2004-08-10 | 2006-06-08 | Wenqing Yao | Amido compounds and their use as pharmaceuticals |
EP1804919B1 (en) | 2004-10-22 | 2011-03-30 | Merck Sharp & Dohme Corp. | Cgrp receptor antagonists |
JP5202954B2 (ja) | 2004-11-10 | 2013-06-05 | インサイト・コーポレイション | ラクタム化合物およびその医薬としての使用 |
KR20070097441A (ko) | 2004-11-18 | 2007-10-04 | 인사이트 산 디에고 인코포레이티드 | 11-β 하이드록실 스테로이드 데하이드로게나제 유형 1의억제제 및 이를 사용하는 방법 |
CN102816081A (zh) | 2005-01-05 | 2012-12-12 | 雅培制药有限公司 | 11-β-羟甾类脱氢酶1型酶的抑制剂 |
JP2008531616A (ja) | 2005-03-03 | 2008-08-14 | エフ.ホフマン−ラ ロシュ アーゲー | II型糖尿病の処置用の11−β−ヒドロキシステロイド・デヒドロゲナーゼのインヒビターとしての1−スルホニル−ピペリジン−3−カルボン酸アミド誘導体 |
JP2008542375A (ja) * | 2005-06-02 | 2008-11-27 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Orl−1受容体モジュレーターとして有用な新規3−スピロ環式インドリル誘導体 |
JP2009508963A (ja) | 2005-09-21 | 2009-03-05 | インサイト・コーポレイション | アミド化合物および医薬組成物としてのその使用 |
WO2007084314A2 (en) | 2006-01-12 | 2007-07-26 | Incyte Corporation | MODULATORS OF 11-ß HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME |
WO2007089683A1 (en) | 2006-01-31 | 2007-08-09 | Incyte Corporation | Amido compounds and their use as pharmaceuticals |
TW200808807A (en) | 2006-03-02 | 2008-02-16 | Incyte Corp | Modulators of 11-β hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same |
US20070208001A1 (en) | 2006-03-03 | 2007-09-06 | Jincong Zhuo | Modulators of 11- beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same |
WO2007130898A1 (en) | 2006-05-01 | 2007-11-15 | Incyte Corporation | TETRASUBSTITUTED UREAS AS MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1 |
JP2009537564A (ja) | 2006-05-17 | 2009-10-29 | インサイト・コーポレイション | 11−βヒドロキシルステロイドデヒドロゲナーゼタイプIの複素環阻害剤およびそれを用いる方法 |
-
2006
- 2006-12-04 EP EP06838967A patent/EP1957494A2/en not_active Withdrawn
- 2006-12-04 CA CA2630492A patent/CA2630492C/en active Active
- 2006-12-04 JP JP2008544424A patent/JP5475288B2/ja active Active
- 2006-12-04 US US11/633,347 patent/US8193207B2/en active Active
- 2006-12-04 AR ARP060105351A patent/AR057965A1/es unknown
- 2006-12-04 KR KR1020087016365A patent/KR101415861B1/ko active IP Right Grant
- 2006-12-04 AU AU2006322060A patent/AU2006322060A1/en not_active Abandoned
- 2006-12-04 WO PCT/US2006/046309 patent/WO2007067504A2/en active Application Filing
- 2006-12-04 BR BRPI0619446-0A patent/BRPI0619446A2/pt not_active IP Right Cessation
- 2006-12-04 TW TW095145021A patent/TW200804382A/zh unknown
- 2006-12-04 EA EA200870019A patent/EA200870019A1/ru unknown
- 2006-12-04 NZ NZ568446A patent/NZ568446A/en not_active IP Right Cessation
-
2008
- 2008-05-19 IL IL191554A patent/IL191554A0/en unknown
- 2008-05-19 CR CR9987A patent/CR9987A/es not_active Application Discontinuation
- 2008-06-05 EC EC2008008503A patent/ECSP088503A/es unknown
Also Published As
Publication number | Publication date |
---|---|
KR20080074214A (ko) | 2008-08-12 |
CA2630492C (en) | 2015-04-14 |
WO2007067504A2 (en) | 2007-06-14 |
JP2009518408A (ja) | 2009-05-07 |
BRPI0619446A2 (pt) | 2011-10-04 |
US20070129345A1 (en) | 2007-06-07 |
KR101415861B1 (ko) | 2014-07-04 |
AU2006322060A1 (en) | 2007-06-14 |
IL191554A0 (en) | 2008-12-29 |
CR9987A (es) | 2008-07-29 |
TW200804382A (en) | 2008-01-16 |
US8193207B2 (en) | 2012-06-05 |
CA2630492A1 (en) | 2007-06-14 |
NZ568446A (en) | 2011-12-22 |
WO2007067504A3 (en) | 2007-11-08 |
ECSP088503A (es) | 2008-07-30 |
EA200870019A1 (ru) | 2008-12-30 |
EP1957494A2 (en) | 2008-08-20 |
JP5475288B2 (ja) | 2014-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR057965A1 (es) | Compuestos de lactama y metodos de uso de los mismos | |
AR059726A1 (es) | Moduladores de 11 beta hidroxil esteroide deshidrogenasa de tipo 1, composiciones farmaceuticas de los mismos, y metodos de uso de los mismos | |
RS54236B1 (en) | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICAL PRODUCTS | |
AR058067A1 (es) | Azepinas inhibidoras de quinasas janus | |
AR062240A1 (es) | Derivados de [1,2,4]triazol[4,3-b][1,2,4]triazinas,composiciones farmaceuticas que los contienen y usos en el tratamiento del cancer y otras enfermedades relacionadas con alteracion de quinasas. | |
AR062677A1 (es) | Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden | |
AR059727A1 (es) | Moduladores de 11- beta hidroxil esteriode deshidrogenasa de tipo 1, composiciones farmaceuticas de los mismos , y metodos de uso de los mismos | |
ES2606197T3 (es) | Moduladores pirrolidina de GPR40 | |
AR039659A1 (es) | Inhibidores de metaloproteinasa de heteroariloxi-aril-espiro-pirimidina-2,4,6-triona n-sustituida metaloproteinasa | |
HRP20150941T1 (hr) | Derivati aminodihidrotiazina kao inhibitori bace u lijeäśenju alzheimerove bolesti | |
AR057995A1 (es) | Pirrolo[2,3-b]piridinas y pirrolo[2,3-b]pirimidinas heteroarilo sustituidas como inhibidoras de quinasas janus | |
AR079648A1 (es) | Inhibidores de la replicacion del virus de la hepatitis c | |
AR073480A1 (es) | Benzamidas, su preparacion y su uso como medicamentos | |
AR057131A1 (es) | Derivados de purina como inmunomodulador | |
AR076228A1 (es) | Piperidinas sustituidas como antagonistas de ccr3 | |
AR073530A1 (es) | Inhibidores de janus quinasas para el tratamiento de ojo seco y otras enfermedades relacionadas con los ojos. inserto oftalmico | |
AR081331A1 (es) | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos | |
AR066669A1 (es) | Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas. | |
CO5560553A2 (es) | Compuestos de alquilamida n-(3-amino-2-hidroxi-propil) sustituidos | |
NO20071067L (no) | Nye cykliske ureaderivater, fremstilling derav og farmasoytisk anvendelse derav som kinaseinhibitorer. | |
AR066445A1 (es) | Inhibidores de la proteina activadora de la 5- lipoxigenasa (flap) | |
AR059942A1 (es) | Derivados de benzamidina y usos relacionados de los mismos | |
DE60315265D1 (de) | Stickstoffhaltige heterocyclische verbindung und arzneimittel davon | |
BRPI0512615A (pt) | compostos de sulfonamida | |
AR055051A1 (es) | Compuestos de tiazol y oxazol y composiciones farmaceuticas que los contienen. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |